Gossamer bio announces second quarter 2023 financial results and provides business update

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced its financial results for the second quarter ended june 30, 2023, and provided a business update. “we are very excited to begin the phase 3 prosera study, the next step on our journey to make seralutinib available to patients with pah," said faheem hasn.
GOSS Ratings Summary
GOSS Quant Ranking